Journal of clinical periodontology · 2011
Clinical and microbiological effects of azithromycin in the treatment of generalized chronic periodontitis: a randomized placebo-controlled clinical trial.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sampaio Eduardo, Rocha Marcelo, Figueiredo Luciene Cristina, Faveri Marcelo, Duarte Poliana Mendes, Gomes Lira Eisla Alline, Feres Magda
Аннотация
AIM: To evaluate the effects of systemic azithromycin (AZM) as an adjunct to scaling and root planing (SRP) in the treatment of generalized chronic periodontitis (ChP).
METHODS: Forty subjects were randomly assigned to receive SRP alone or combined with AZM (500 mg/day) for 5 days (n=20/group). Clinical and microbiological examinations were performed at baseline, 6 months and 1-year post-SRP. Nine plaque samples per subject were analysed by checkerboard DNA-DNA hybridization for 40 bacterial species. Differences between groups were assessed using the Mann-Whitney test and over time using Friedman and Dunn's tests.
RESULTS: No statistically significant differences were observed between groups for any parameters evaluated at 1-year post-treatments. Both therapies equally reduced the mean probing depth (PD) (SRP: 3.83 ± 1.92, AZM: 3.45 ± 1.74) and improved the mean clinical attachment (SRP: 2.35 ± 1.70, AZM: 2.68 ± 1.76) in sites with initial PD7 mm (primary outcome variable) between baseline and 1 year. The mean counts and proportions of several periodontal pathogens were reduced, and those of host-beneficial species were increased after treatments. Nonetheless, an important recolonization with red complex species was observed in both groups over the course of the study.
CONCLUSION: The data of the present study suggest no adjunctive benefit of AZM in the treatment of generalized ChP.
METHODS: Forty subjects were randomly assigned to receive SRP alone or combined with AZM (500 mg/day) for 5 days (n=20/group). Clinical and microbiological examinations were performed at baseline, 6 months and 1-year post-SRP. Nine plaque samples per subject were analysed by checkerboard DNA-DNA hybridization for 40 bacterial species. Differences between groups were assessed using the Mann-Whitney test and over time using Friedman and Dunn's tests.
RESULTS: No statistically significant differences were observed between groups for any parameters evaluated at 1-year post-treatments. Both therapies equally reduced the mean probing depth (PD) (SRP: 3.83 ± 1.92, AZM: 3.45 ± 1.74) and improved the mean clinical attachment (SRP: 2.35 ± 1.70, AZM: 2.68 ± 1.76) in sites with initial PD7 mm (primary outcome variable) between baseline and 1 year. The mean counts and proportions of several periodontal pathogens were reduced, and those of host-beneficial species were increased after treatments. Nonetheless, an important recolonization with red complex species was observed in both groups over the course of the study.
CONCLUSION: The data of the present study suggest no adjunctive benefit of AZM in the treatment of generalized ChP.